Onesource Specialty Pharma Limited
OneSource Specialty Pharma Ltd. released its Q4 and full year FY26 earnings call transcript. The company reported Q4 revenue of Rs.4,282 million and adjusted PAT of Rs.390 million, emphasizing strong sequential growth and the reaffirmation of its US$400 million FY28 organic revenue target.
May 19 2026 18:05:00
Onesource Specialty Pharma gets government nod for Unit II expansion project
Onesource Specialty Pharma has received in-principle approval from the Government of Karnataka for the expansion of its Unit II facility. This approval falls under the Karnataka Industrial Policy 2025–30 and includes incentives and concessions, aiming to enhance the company's manufacturing capacities to serve global partners.
May 16 2026 15:05:00
Onesource Specialty Pharma Limited
Onesource Specialty Pharma Ltd received in-principle approval from the Government of Karnataka for its Unit II expansion project. This approval includes incentives and concessions under the Karnataka Industrial Policy 2025-30, aimed at enhancing manufacturing capacities for global partners.
May 16 2026 13:05:00
Onesource Specialty Pharma Ltd - 544292 - General-Update
Onesource Specialty Pharma secured in-principle approval from the Karnataka Government for its Unit II expansion project. This approval includes incentives and concessions under the KIP 2025-30, enhancing manufacturing capacities for global partners.
May 16 2026 13:05:00
Onesource Specialty Pharma Ltd - 544292 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Onesource Specialty Pharma announced strong Q4 FY26 results with revenue growing 47% QoQ to Rs.4,282 million and EBITDA expanding over 5x. The company also reaffirmed its FY28 guidance.
May 13 2026 13:05:00
Onesource Specialty Pharma Ltd - 544292 - Board Meeting Outcome for Intimation Of The Outcome Of The Board Meeting Dated May 13, 2026 For Approval Of The Standalone And Consolidated Financial Results For The Quarter And Year Ended March 31, 2026
Onesource Specialty Pharma board approved FY26 financial results, reporting a cons. net loss of ₹738.03 mn, significantly widening from ₹179.71 mn loss in FY25. Also appointed B S R & Co LLP as new statutory auditors for 5 years, replacing Deloitte Haskins & Sells.
May 13 2026 13:05:00
Onesource Specialty Pharma Ltd - 544292 - Board Meeting Intimation for Intimation Regarding Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements), Regulations, 2015
Onesource Specialty Pharma's Board of Directors is scheduled to meet on May 13, 2026. The agenda includes considering and approving the audited financial results for the quarter and year ended March 31, 2026.
May 07 2026 18:05:00
Onesource Specialty Pharma Limited
Onesource Specialty Pharma Ltd. partner Orbicular received Health Canada approval for a generic version of Ozempic® (semaglutide injection). This enables commercialization for the first two generic entrants in Canada's significant semaglutide market, with OneSource supporting manufacturing from its US FDA-approved facility in Bengaluru.
May 04 2026 08:05:00
Onesource Specialty Pharma Limited
Onesource Specialty Pharma Ltd. partner Orbicular received Health Canada approval for a generic version of Ozempic® (semaglutide injection). This enables commercialization for the first two generic entrants in Canada's significant semaglutide market, with OneSource supporting manufacturing from its US FDA-approved facility in Bengaluru.
May 04 2026 08:05:00
Onesource Specialty Pharma Ltd - 544292 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
OneSource Specialty Pharma's partner, Orbicular, received Health Canada approval for a generic version of Ozempic (semaglutide injection). This enables commercialization in Canada's significant market, with OneSource providing manufacturing from its US FDA-approved facility, strengthening its CDMO presence.
May 04 2026 08:05:00
Read More